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Introduction
Macrophage activation syndrome (MAS) is a severe com-
plication of autoimmune diseases. It is more often asso-
ciated with Systemic Juvenile Idiopathic Arthritis (sJIA). It
is difficult to distinguish the MAS from a flare of sJIA,
infection or medicinal side effects. The MAS can occur
during a flare, an infection, a change in the medication or
as a side effect of the treatment administered for the treat-
ment of sJIA. Paradoxically have been reported MAS cases
in patients with sJIA treated with anti IL-1 or anti IL-6R.
Objectives
We report two cases of sJIA who developed MAS during
the treatment with biological therapy.
Methods
Revison of two cases of MAS associated with sJIA treated
with biological therapy in our clinic.
Results
Case1
Girl diagnosed at 9 years of sJIA, treated with Prednisone
and then MTX for persistent arthritis. A few yers later,
Anakinra treatment is started for persistent joint activity
despite MTX, suspended after 5 weeks of treatment for
suspected unconfirmed septic arthritis, treated with anti-
biotics and anti-inflammatory. A month after the resolu-
tion of the infectious process it was restart Anakinra,
detecting eight days later deterioration of liver function
and subsequent development of a analytical and clinically
symptoms compatible with MAS. The clinical picture
improved gradually after initiation of cyclosporine and
high dose of prednisone, achieving complete remission.
Currently treated with Tocilizumab with good clinical out-
come, without new MAS episode.
Case2
Patient diagnosed of sJIA according to ILAR criteria at 2
years of age, debuting with tipically clinical, laboratory and
histological MAS, coinciding with very high disease
activity. At 4 years of age it is initiated Etanercept that is
suspended 1 year later for ineffectiveness. At age 8 he start
Anakinra with good clinical response, treatment that is
maintained up to 14 years when it is suspended for clinical
remission and local side effects (pain). Six months after the
suspension he presents a new flare with new joint and sys-
temic activity that is treated with Tocilizumab alone, with-
out Prednisone. After the second infusion of Tocilizumab
he presents upper respiratory infection, treated with
Amoxicillin and anti-inflammatory treatment. Several days
later he is hospitalized with clinical and laboratory tests
compatible with MAS. The bone marrow biopsy con-
firmed the presence of hemofagocitos. The microbiological
tests detected recent Ebstein Barr Virus infection. It was
initiated treatment with Cyclosporine i.v Methylpredniso-
lone with resolution of symptoms.
Conclusion
To our knowledge, there are reported a few cases of MAS
coinciding with the anti IL -1 or anti IL -6R treatments
administered sJIA therapy. In recently published clinical
trials, conducted to evaluate the efficacy and safety of
treatment of IL -1beta monoclonal antibody and anti IL-6
receptor antibody, it was detected a few cases of MAS.
The mechanism of occurrence of MAS during these thera-
pies is still unclear. The hypothesis that arises is that the
blockade of proinflammatory cytokines and /or an infec-
tious trigger could create an imbalance in the regulation of
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cytokines and activation of T lymphocytes and macro-
phages with a significant increase of proinflammatory
cytokines, which may trigger a macrophage activation
syndrome. Our two patients have had prior to the
development of MAS an intercurrent infection, receiving
antibiotic and anti-inflammatory treatment. The second
case had a history of SAM prior to any treatment.
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